Regdanvimab for patients with mild-to-moderate COVID-19: a retrospective cohort study and subgroup analysis of patients with the Delta variant.

"Declaration of competing interest Y.R. Jang and J.Y. Kim have been investigators for COVID-19 clinical trials sponsored by Bukwang Pharmaceutical, Daewoong Pharmaceuticals, Enzychem Lifesciences, GC Pharma, and Pfizer, outside the scope of the submitted work, and for Celltrion, Inc., within the scope of the submitted work. Y.J. Oh has no competing interests to declare."

"Funding Celltrion Inc., the manufacturers of regdanvimab, provided funding to Incheon Medical Center for the conduct of this study and contributed to performing the statistical analyses. The study investigators were responsible for study design, conduct, data collection, interpretation, and manuscript preparation. All authors reviewed and approved the final version of the manuscript. Celltrion Inc. reviewed the manuscript throughout development for scientific accuracy."